Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We know it's positive results....but how positive
It is nice to have an educated VTVT poster here. Cant wait until tomorrow AM. Hoping we get more feedback tomorrow otherwise we wait until Monday.
VtVt data wither the 6 pt adas improvement over Placebo is impressive. I thought the n= was enough to show advancement.. and I also thought the target was specific enough and large enough to move forward.
If I am reading this right ..I didn’t like that lesser dosage had effect and not higher.. Why would not a higher dosage have at least the same effect?
Leads me to believe there is a gate that swings both ways and that gets more complicated to properly prescribe I would think.. maybe I worry about silly things..
It is exciting to find medicines that have cognitive and demonstrated effect on dementia patients.
Currently not owner but that could change
VTVT should run green today, tomorrow and next week. The next step would be FDA approval but I expect more good news ahead of that. The VTVT poster presentation happens Friday in Spain and they are 9 hours ahead of us. That would be sometime early tomorrow AM. The float is tiny between 3 to 6 million shares and insiders now own about 80% of the OS.
This is HUGE! VTVT should be over $10.00 in the days ahead. Most figured $100.00 plus on good news!
vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer's and Diabetes at the 11(th) Clinical Trials on Alzheimer's Disease (CTAD)
You wish it would be, but it shouldn’t because the posthoc subgroup data mining does warrant it.
VTV now have to discuss a ‘potential’ way forward with the FDA. More time more money and no revenue.
Most likely means share price heading down until Perelman next time spends some money to prop up the share price.
IN APRIL 2018
vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 9, 2018-- vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary efficacy endpoint. Patients taking azeliragon compared with placebo did not improve in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb).
IN JUNE 2018
View printer-friendly version
<< Back
vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.
+++++++++++++++++++++++++
However, consistent with findings in Part A and the Phase 2b trial, lower maximal plasma concentrations of azeliragon in Part B were associated with improvements in efficacy relative to placebo.
“We are eager to obtain early feedback from the FDA based on the results we have achieved and the data that we have observed associating lower plasma levels of the drug and improved efficacy,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “As a result, we believe that azeliragon has the potential to address the pressing unmet need in Alzheimer’s disease.”
While in April and in June 2018 topline results were announced that the A-Study and the B-Study did not meet the co-primary endpoints and clinical trials were ended, subsequent post-hoc subgroup analyses have shown populations that experienced positive benefits.
SO WE ARE WAITING FOR THE RESULTS OF THESE SUB-GROUP
VTVT should be in the $10.00 to $50.00 range on this news. Patience. They can manipulate this tiny float to get hat they want and we can gap up a few dollars tomorrow and Friday. Meanwhile day traders mess up tiny float stocks and we all know this.
flip, swing, sell....we don't hold and hope....
Jus like a couple weeks back when VTVT ran from .70's to over $6.00 in a flash. Tiny float can move up or down fast. Bottom line this news is worth $10.00 plus easy IMO. Give it a couple days.
wow, awseome insights cj 4.25, to 3.32 in a flash, glad my guys got out 4-4.20 area
VTVT has a tiny float and with day traders we have seen it trade thin up and down, the Nasdaq moved down an stop losses hit. I still believe VTVT should be over $6.00 and $10.00 in the days ahead. Insiders own 82% of the OS now!
Agreed, run is done for now, play was from $3.25+ to $4.25, EZ money last few days.....
Been trading it for a week, looks like diluted w shelf offering here...find out 2-3 days.....all out on the spike over $4
Those are some really nice price targets! VTVT
Wow
I am holding long then
(NASDAQ:VTVT). Other Wall Street experts have also recently posted reports on these shares. ROTH Capital gave the stock a Buy rating, while setting a price target at $17 in a research note from Thursday, March 8th, 2018. Northland Capital posted a $28 price target for vTv Therapeutics Inc. stock and rated the stock as an Outperform in a research note dated Thursday, February 8th, 2018.
Hopes so
I love bio play
VTVT should be $20.00 plus on this news IMO refer to the recent chart and low float. Patience
Very promising
Let’s wait and see.
Man-o-man! Insiders have massive confidence VTVT
Sounds good
Thks
VTVT should see a 100% to 200% run today and likely more this week. The float is only 3 to 6 million shares and insiders own 82% of the OS now.
I think so
Good luck
Once VTVT is over $6.00 it will not take much to run over $10.00. Remember we ran 500% to 600% in only a day and a half in the past couple weeks refer to the charts. The float is tiny and this is huge news.
Market likes this news
Yes downwards fast.
Wow!> thanks for heads up CJ.
Nice news
Any pps prediction?
Yep week data from small subgroup posthoc analysis with borderline stat sig.
vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer's and Diabetes at the 11(th) Clinical Trials on Alzheimer's Disease (CTAD) Conference
9:00 AM ET 10/24/18 | BusinessWire
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer's Disease
Nearly 40 percent of Medicare Beneficiaries with Dementia Also Suffer from Diabetes, a Large Population to Potentially Benefit
HIGH POINT, N.C.--(BUSINESS WIRE)--October 24, 2018--
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer's disease (AD) and diabetes, today announced that a subgroup analysis from the azeliragon Phase 3 STEADFAST trial was presented at the 11(th) Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain. The data presented at the conference included post-hoc, positive data indicating a potential benefit of treatment with azeliragon in AD patients with type 2 diabetes. It is estimated that nearly 40 percent of Medicare beneficiaries age 65 and older with dementia also have diabetes (Alzheimer's Association. 2018 Alzheimer's Disease Facts and Figures).
In a poster presentation titled "Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial," researchers from vTv reviewed results from a post-hoc subgroup analysis from the company's STEADFAST trial. This subgroup included 55 patients with type 2 diabetes (defined by glycosylated hemoglobin (HbA1c) of greater than 6.5% at baseline; HbA1c greater than 7.7% was an exclusion criterion at screening) and a clinical diagnosis of Alzheimer's disease in the combined A-Study and B-Study of the STEADFAST trial. The azeliragon-treated group in the A-Study (n=18) demonstrated a 6.1 point benefit on ADAS-cog relative to the placebo group (n=8), which was nominally statistically significant (p = 0.005), and a 1.7 point benefit on CDR-sb relative to placebo (p = 0.08) after 18 months of treatment.
When conducting this subgroup analysis on pooled data from both the A-Study and B-Study and comparing change from baseline at 12 months (B-Study was discontinued at 12 months), the azeliragon subgroup (n=33) demonstrated a 3.5 point benefit on ADAS-cog (p = 0.01) relative to the placebo group (n=22), and a 0.7 point benefit on CDR-sb (p = 0.24) relative to placebo. A copy of the poster can be found on the publications page of the company's website.
"The association between diabetes and dementia is well documented and these findings are supported by the mechanism of action of azeliragon. The Receptor for Advance Glycation Endproducts (RAGE) has been implicated in both the pathogenesis of Alzheimer's disease and diabetic complications. These results, albeit from a smaller number of patients, reinforce this hypothesis and may open a new therapeutic approach for the treatment of not only dementia but also other complications of diabetes," said Carmen Valcarce, Chief Scientific Officer of vTv Therapeutics.
"We are encouraged by the positive benefits experienced by the diabetic patients in this study." said Steve Holcombe, Chief Executive Officer of vTv Therapeutics. "With over 400 million people with diabetes around the world who are at a higher risk of developing dementia, we think these findings warrant further investigation of this therapy for this unmet medical need," added Mr. Holcombe.
About Azeliragon
Azeliragon, also known as TTP488, is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts, RAGE. vTv Therapeutics discovered and developed azeliragon using its proprietary drug discovery platform, TTP Translational Technology(R). A broad range of human pathologic and experimental biologic investigation suggests that RAGE ligand interactions lead to sustained inflammatory states that play a role in chronic diseases such as diabetes, inflammation, and Alzheimer's disease.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as treatment of inflammatory disorders.
About STEADFAST
The STEADFAST study, two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials (A-Study and B-Study), was designed to investigate the safety and efficacy of azeliragon as a potential treatment for patients with mild Alzheimer's disease. The 18-month study targeted enrollment of 800 patients (400 in each trial). The first trial enrolled patients in the United States and Canada who had a clinical diagnosis of mild Alzheimer's disease and an MRI consistent with this diagnosis. Enrollment of the second trial included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa. While in April and in June 2018 topline results were announced that the A-Study and the B-Study did not meet the co-primary endpoints and clinical trials were ended, subsequent post-hoc subgroup analyses have shown populations that experienced positive benefits.
Yep the company will say that their posthoc subgroup analysis warrants further studies and money thrown at it. The stock will sell on that news.
JMHO
VTVT: findings from the STEADFAST study suggest that lower maximal plasma concentrations of azeliragon are associated with improvements in efficacy relative to placebo. These findings are consistent with published data from the phase 2b study (Burstein et al. BMC Neurology 2014, 14:12).
Relying upon the program’s Fast Track Designation status and study results to date, the Company will pursue expedited discussions with the Food and Drug Administration (FDA) to propose a pathway for further clinical development in support of regulatory approval of azeliragon.
VTVT with positive results could be worth $200.00. I was reading up on the new delivery method to get FDA approval for VTVT's Azeliragon under their new studies and I also found this, it was written yesterday. I think this could get VTVT alot of attention in the days ahead. It also describes what happened to the market cap of BIIB and the single day $12 billion increase in market cap for BIIB back in July when they announced positive phase 2 results.
Alzheon: A Bold And Novel Approach To Treating Alzheimer's With A Solid Chance Of Success
Oct. 22, 2018 6:11 PM ET
About: Alzheon (ALZH), Includes: AXON, BIIB, VTVT
Do you have a link to the Analyst information on how the VTVT Azeliragon data will be presented? I do know about the different delivery method and the last trials showed promise.
I agree with your point
Let’s see what happen tmrw and Friday
Good luck
VTVT is so much fun when it runs. Look at the chart in the past couple weeks. Tiny float ran from .70's to $6.09 in 2 days from lows to highs. The float is pretty locked around $3.75 now IMO. Any volume run and VTVT will fly back over $6.00 and head to $10.00 fast. If we get good news over $10.00 easy and if it is really good news we have a $200.00 stock here base don others great DD.
I bought some here
Looks promising this week
Likewise, and I actually really hope the data is good because we badly need better AD treatment.
I did, but got out with an excellent return that I'd like to keep.
Then don't invest. I am holding my VTVT shares tight. I love the low float here and huge insider holdings.
Biogen and other companies go to CTAD and other scientific conferences to share their learning. Last time Biogen did that for their AD drugs, the market was not so impressed and if you ask me for good reason - the same sort of reason why I think VTV will tank post CTAD.
Just IMO.
It would seem foolish to me to schedule 2 presentations this week at the 11th annual Alzheimer's conference if they did not have good VTVT data. Most other companies are not presenting.
I know and curious to buy more if no confidence in the data.
However, compared to the run up in the very small stock float from relatively small Perelman purchases, the MCap of VTV has gone up significantly on paper making those purchases very worthwhile.
Now how exactly Perelman would benefit from that even if the data is less than good is anybody’s guess.
Insiders Private Purchase of Perelman. He owns 82% of VTVT
https://fintel.io/n/perelman-ronald-o
Other than the typical Dow and big boards red effect this AM where they gapped us down premarket for no reason VTVT is fine. They just released all of the VTVT institutional holders also.
I know, but I fear retail will be very disappointed and fleeced post the CTAD VTVT presentation of posthoc mined subgroup data.
Happy to be wrong though as AD sure needs any treatment more useful that SOC if even for a subgroup of patients.
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
613
|
Created
|
01/03/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |